Low frequency glatiramer acetate therapy
US8969302B2 · kind B2 · utility
14Cited by
33References
12Claims
0Family size
Assignee
Inventor
Key dates
| Filing date | Feb 19, 2013 |
| Grant date | Mar 3, 2015 |
| Priority date | — |
| Expiry date | Feb 19, 2033 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61P3/10
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
A method of alleviating a symptom of relapsing-remitting multiple sclerosis in a human patient suffering from relapsing-remitting multiple sclerosis or a patient who has experienced a first clinical episode and is determined to be at high risk of developing clinically definite multiple sclerosis comprising administering to the human patient three subcutaneous injections of a therapeutically effective dose of glatiramer acetate over a period of seven days with at least one day between every subcutaneous injection so as to thereby alleviate the symptom of the patient.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.